TICKERNERD
Menu
PBHPBHHealthcare · Drug Manufacturers - Specialty & Generic

PBH Stock Forecast: Prestige Consumer Healthcare, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$53
+7.55% on the day

The 7 Wall Street analysts covering Prestige Consumer Healthcare, Inc. hold a median 12-month price target of $70 — +31.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 3 Nov 2026 — in the upper half.

Market cap
$2.3B
Ticker Nerd rank
68/ 100
Median analyst target
$70
Analysts covering
7
Revenue$265.7M+6.5% y/y
Operating income$52.5M
Net income$29.2M
Free cash flow$67.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+11.5%
1M
+17.7%
YTD
−13.6%
1Y
−12.0%
From 52W high
−24.1%
From 52W low
+19.0%
$45
$70
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PBH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Prestige Consumer Healthcare, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Nov 2026
68/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
98
Value
95
Quality
87
Revisions
77
Issuance
43
Growth
39
Momentum
37
Size
33
Accruals
30

Volatility (98): The share price has been relatively steady.

Accruals (30): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PBH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PBH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$50$60$70$80Jan 26Apr 26Jul 26Oct 26PBHHigh $75Median $70Low $55

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
5 Buy2 Hold0 Sell
Low $55Median $70High $75

The green dot is the last close — the median target sits +31.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 May 2026Canaccord GenuityMaintainsBuy$86 → $72
14 May 2026OppenheimerDowngradePerform—
7 May 2026OppenheimerMaintainsOutperform—
2 Feb 2026JefferiesMaintainsHold—
7 Nov 2025Canaccord GenuityMaintainsBuy—
27 Oct 2025JefferiesMaintainsHold—
21 Oct 2025OppenheimerMaintainsOutperform—
8 Aug 2025Canaccord GenuityMaintainsBuy—
21 Mar 2025RBC CapitalMaintainsSector Perform—
13 Feb 2025OppenheimerMaintainsOutperform—
7 Feb 2025Canaccord GenuityMaintainsBuy—
7 Feb 2025DA DavidsonMaintainsBuy—
11 Nov 2024DA DavidsonMaintainsBuy—
24 Sept 2024JefferiesAssumesHold$70 → $76
28 Aug 2024DA DavidsonMaintainsBuy—
9 Aug 2024Canaccord GenuityMaintainsBuy—
9 Aug 2024DA DavidsonMaintainsBuy—
21 June 2024DA DavidsonUpgradeBuy—
21 May 2024Canaccord GenuityMaintainsBuy—
16 May 2024DA DavidsonMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

PBH appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

PBH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Prestige Consumer Healthcare, Inc. returned −12.0% against +12.9% for the S&P 500, dividends included.

PBH vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Jan 26Apr 26Jul 26Oct 26PBHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PBH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−0.1%
Analysts raising
1
Analysts cutting
1
Fundamentals

Prestige Consumer Healthcare, Inc. (PBH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
13.8×

Cheaper than 48% of US stocks

Price / sales
2.1×

Cheaper than 50% of US stocks

Price / book
1.2×

Cheaper than 64% of US stocks

EV / EBITDA
13.3×

Cheaper than 27% of US stocks

Growth & margins
Revenue growth (YoY)
6.5%

Higher than 44% of US stocks

Earnings growth (YoY)
−38.5%

Higher than 14% of US stocks

Gross margin
51.3%

Higher than 63% of US stocks

Operating margin
20.8%

Higher than 80% of US stocks

Net margin
15.6%

Higher than 78% of US stocks

Returns & dividend
Return on equity
9.1%

Higher than 61% of US stocks

Return on assets
4.6%

Higher than 74% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Prestige Consumer Healthcare, Inc. (PBH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Prestige Consumer Healthcare, Inc. has a market value of $2.3B and an enterprise value of $4.3B.

  • Revenue in the twelve months to 30 June 2026: $1.1B. The latest quarter grew 6.5% year on year.

  • Net income over the same four quarters: $172.0M, a 15.6% net margin.

  • Diluted earnings per share, trailing twelve months: $3.57.

  • Free cash flow in the twelve months to 30 June 2026: $235.4M.

  • Prestige Consumer Healthcare, Inc. spent $121.5M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 47.4M.

  • Trailing P/E: 13.8×; forward P/E: 9.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Prestige Consumer Healthcare, Inc. employs 890 people — $1.2M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

PBH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
PBHPrestige Consumer Healthcare, Inc.$2.3B68
SUPNSupernus Pharmaceuticals, Inc.$2.4B—
TRLVTrulieve Cannabis Corp.$2.2B89
PRGOPerrigo Co. Plc$2.2B76
BCRXBioCryst Pharmaceuticals, Inc.$2.1B86
XERSXeris Biopharma Holdings, Inc.$1.9B86
RGCRegencell Bioscience Holdings Ltd.$3.0B22

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Prestige Consumer Healthcare, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PBH news & analysis

Riverwater Small Cap Strategy Q3 2026 Portfolio Update

Seeking Alpha · 28 Oct 2026neutral

Riverwater’s Small Cap strategy slightly underperformed the Russell 2000 in Q3 2026 as small-cap stocks broadly declined. AtriCure and Red Violet were top contributors, while Kodiak Gas Services and PDF Solutions were top detractors; the strategy initiated IRadimed and replaced Talkspace after its acquisition.

Why it matters — The excerpt does not mention Prestige Consumer Healthcare, so it provides no company-specific information for PBH watchers.

Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now?

Zacks Investment Research · 15 Oct 2026neutral

Zacks Investment Research says Prestige Consumer’s brand-building efforts, acquisitions and e-commerce growth support revenue gains in fiscal 2027. It also highlights competition and currency risks as ongoing challenges.

Why it matters — PBH watchers may weigh the cited growth drivers against competitive and currency-related risks.

Best Value Stocks to Buy for October 1st

Zacks Investment Research · 1 Oct 2026positive

On October 1, 2026, Prestige Consumer Healthcare, Inc. (PBH) was added to Zacks Investment Research's list of Zacks Rank #1 (Strong Buy) value stocks, alongside BP. The inclusion highlights PBH as a recommended value stock on that date.

Why it matters — PBH watchers would note that the company received a Strong Buy value-stock designation from Zacks, which could draw attention to the stock.

PBH vs. NEOG: Which Stock Is the Better Value Option?

Zacks Investment Research · 30 Sept 2026neutral

Zacks Investment Research published an analysis comparing Prestige Consumer Healthcare (PBH) and Neogen (NEOG) as potential value options for investors interested in Medical - Products stocks. The piece examines which of the two companies may present itself as the better value choice.

Why it matters — PBH watchers would be interested in how the company's valuation stacks up against a peer in the same sector.

FAQ

Frequently asked questions about PBH stock

What is the PBH stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Prestige Consumer Healthcare, Inc. have a median 12-month price target of $70, with estimates ranging from $55 to $75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PBH stock a buy right now?

Of the 7 analysts covering Prestige Consumer Healthcare, Inc., 5 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Prestige Consumer Healthcare, Inc. 68 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PBH?

As at 3 Nov 2026, Prestige Consumer Healthcare, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).

Will PBH stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +31.4% from the last close, and Ticker Nerd's factor model ranks Prestige Consumer Healthcare, Inc. 68 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PBH stock forecast for 2030?

No analyst covering Prestige Consumer Healthcare, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PBH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $55 to $75 over the next 12 months.

How has PBH stock performed over the past year?

Prestige Consumer Healthcare, Inc. returned -12.0% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Prestige Consumer Healthcare, Inc. do?

Prestige Consumer Healthcare Inc. is a consumer healthcare company that develops, manufactures, markets, distributes, and sells branded over-the-counter health and personal care products.

What is the latest news on PBH?

The most recent item we track (Seeking Alpha, 28 Oct 2026): "Riverwater Small Cap Strategy Q3 2026 Portfolio Update". Riverwater’s Small Cap strategy slightly underperformed the Russell 2000 in Q3 2026 as small-cap stocks broadly declined. AtriCure and Red Violet were top contributors, while Kodiak Gas Services and PDF Solutions were top detractors; the strategy initiated IRadimed and replaced Talkspace after its acquisition.

Company

About Prestige Consumer Healthcare, Inc.

Prestige Consumer Healthcare Inc. is a consumer healthcare company that develops, manufactures, markets, distributes, and sells branded over-the-counter health and personal care products. Prestige Consumer Healthcare Inc. focuses on everyday self-care categories such as pain relief, sore throat care, eye care, digestive health, skin protection, diaper rash treatment, ear wax removal, women’s care, and oral care. Its portfolio includes well-known products sold through mass merchandisers, drugstores, grocery retailers, dollar stores, convenience channels, club stores, and e-commerce outlets across North America, Australia, and other international markets. The company operates through North American OTC Healthcare and International OTC Healthcare segments, giving it broad exposure to consumer wellness products used for common, recurring health needs. Prestige Consumer Healthcare Inc. plays a specialized role in the market as a branded over-the-counter healthcare provider with a portfolio centered on established consumer brands.

CEO Mr. Ronald M. Lombardi CPA · 890 employees · United States · https://www.prestigebrands.com